Cannabis Science Inc (CBIS) 0.0710 $CBIS
AIDS Related Kaposi's Sarcoma Therapeutics Pipeline Review 2014 - 5 Companies & 5 Drug Profiles
M2 - 2 hrs 24 mins ago
Research and Markets (http://www.researchandmarkets.com/research/2fddlb/aids_related) has announced the addition of the "AIDS - Related Kaposi's Sarcoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for AIDS - Related Kaposi's Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for AIDS - Related Kaposi's Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Aphios Corporation - CytRx Corporation - Cannabis Science, Inc. - Biogenomics Limited Drug Profiles - aldoxorubicin - selumetinib sulfate - paclitaxel nanosomal - CS-TATI-1 - interferon alfa-2a For more information visit http://www.researchandmarkets.com/research/2f...ds_related
Cannabidiol "CBD" Products Lead Industrial Hemp Sales As Scientific & Clinical Studies Underscore CBD's Potential - Company Exceeds Sales as Shipping Orders Begin
PR Newswire - Wed Sep 10, 7:45AM CDT
Marijuana & Cannabis industry experiences continued growth as emerging companies develop new cannabis opportunities as a result of recent clinical studies, reports provided on latest product developments from various sector related companies: Flameret Inc. (OTC: FLRE), Cannabis Science Inc. (OTC: CBIS), Medical Marijuana Inc. (OTC: MJNA), Terra Tech Corp. (OTC: TRTC), American Green Inc. (OTC: ERBB) and Easton Pharmaceuticals Inc. (OTC: EAPH)
NTRR: Feds Increase Cannabis Production as Demand Soars
Business Wire - Thu Sep 04, 4:00AM CDT
As Neutra Corp. (OTCBB:NTRR) prepares to debut revolutionary new indoor horticulture tools in a hungry marketplace, the demand for medical cannabis has grown so strong that even the federal government is increasing its production of the herb.
Cannabis Science Provides Updated Guidance on its Current Pre-Clinical Drug Development Programs Beginning with the Scientific Cannabis Cultivation Programs in Europe and North America, Testing Multiple Cannabis Strains for Multiple Critical Ailments
PR Newswire - Tue Aug 26, 12:17PM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to provide a guidance report on its current pre-clinical drug development programs underway, beginning with the scientific cannabis cultivation programs in Europe and North America, testing multiple cannabis strains for multiple critical ailments.
Cannabis Science, Inc. (CBIS) In Final Negotiations To Acquire British Columbia Company That Has Submitted 'Marihuana For Medical Purposes' License Application To Health Canada
PR Newswire - Mon Aug 25, 10:17AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that it is in the final stages of negotiations for the acquisition of a company that has applied for a "Marihuana for Medical Purposes" (Canada) license with Health Canada. The application includes a site located in British Columbia, Canada with a highly experienced and professional team. The target company currently produces cannabis under the "Marihuana Medical Access Regulations" (Canada).
Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France
PR Newswire - Fri Aug 22, 7:51AM CDT
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce its sponsorship of UFCM iCare's third international medical cannabis conference taking place at the Faculty of Medicine of Strasbourg, France, on October 22, 2014. The multilingual conference brings together industry experts with other stakeholders, such as researchers, health professionals, and patients, to discuss the development of medical cannabis in Europe and North America.
NTRR: U.S. Cannabis Market Poised to Grow with November Ballots
Business Wire - Thu Aug 21, 7:31AM CDT
The U.S. cannabis market appears primed to continue its unprecedented growth this year with 17 votes on the herb scheduled for the November general election. By that time, Neutra Corp. (OTCBB: NTRR) plans to be in production on its groundbreaking new Diamond Anvil vaporizer pen.
Cannabis Science, Inc. (CBIS) Increases Equity Position to 50.1% in Michigan Green Technologies LLC, Positioning Company as Leader in Evolving Michigan Medical Cannabis and Hemp Industries
PR Newswire - Mon Aug 11, 10:16AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, signs a binding letter of intent with its existing Michigan partners, increasing Cannabis Science's equity position from 20% to 50.1% in its joint venture in the Michigan medical cannabis and hemp markets, Michigan Green Technologies LLC (MGT).
Cannabis Science In Final Negotiations To Establish Its First Medical Cannabis Facilities In Canada
PR Newswire - Thu Aug 07, 10:55AM CDT
Cannabis Science, Inc. (OTC-QB:CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, is in the final stages of launching a new joint venture company for the purpose of acquiring, financing, building, owning and operating medical cannabis facilities, including dispensaries and growing operations, throughout Canada.
NTRR: Small Businesses Seize Big Opportunities in Cannabis Industry
Business Wire - Thu Aug 07, 9:16AM CDT
Rapidly evolving laws and enforcement have opened major opportunities in the U.S. cannabis sector for start-ups and small businesses. As new markets continue to emerge, Neutra Corp. (OTCBB: NTRR) is preparing to release new technology to capitalize on the nascent industry's "gold rush."
Cannabis Science, Inc. (CBIS) Encouraged by Florida Medical Cannabis Voter Support of 88 Percent; Florida Referendum in November Seen as Key Tipping Point
PR Newswire - Tue Aug 05, 10:23AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is encouraged by recent polling data by Quinnipiac University showing widespread support among voters in Florida for November's upcoming constitutional referendum on medical cannabis. The most recent study shows 88 percent of Florida voters are in favor of cannabis for medical uses.
Novus Acquisition & Development MMJ MedPlan Network Is A Contender
ACCESSWIRE - Tue Aug 05, 8:48AM CDT
Whitefish, MT / Aug 5, 2014 / As the Green Rush continues to gain political and cultural momentum across the country, shockwaves are being felt by all the primary players, from suppliers to patients, as the rapidly growing marijuana (MMJ) sector blows through each successive regulatory barrier. Even though 23 states (including DC) have enacted laws to legalize medical marijuana, the sector remains highly fragmented.
NTRR: Cannabis Boom Continues as New Markets Open
Business Wire - Tue Aug 05, 4:41AM CDT
As Neutra Corp. (OTCBB: NTRR) prepares to begin manufacturing and distributing its subsidiary's groundbreaking new vapor pen product, demand for cannabis-related products has taken another jump as recreational sales begin in the state of Washington.
Cannabis Science Initiates Pre-Clinical Studies on Cannabinoid Formulations in Neurological Diseases Including Sleep Disorders with the Highly Reputable Institute for Health and Science on Ageing - INRCA - in Italy
PR Newswire Europe - Mon Aug 04, 8:25AM CDT
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is announcing that through its wholly-owned subsidiary, Cannabis Science International Holding BV, has signed an agreement with the prestigious Institute for Research, Hospitalization and Health Care on Ageing (INRCA) in Italy. The agreement provides for toxicity and efficacy studies of cannabinoid formulations performed in animal models for neurobehavioral diseases including sleep disorders.
Dr. Robert Melamede Joins Cannabis Professional University in Charlotte, NC at Business Seminar
PRWeb - Mon Aug 04, 5:37AM CDT
Cannabis Professional University announces that world-renowned medical cannabis research expert Dr. Robert Melamede, a Ph.D. in Molecular Biology and Biochemistry, has been added to the list of speakers at the Cannabis Business Seminar in Charlotte, North Carolina on Sunday August 3 from 9 am until 5 pm at the Sheraton Charlotte Airport Hotel.
Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders
PR Newswire - Thu Jul 31, 10:07AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that it has commenced production of multiple strains of cannabis and European Union certified hemp varieties to initiate scientific research to select the best strains for development of proprietary formulations for clinical drug development to bring the cannabis formulations to market for critical ailments such as cancer and neurological disorders.
CBIS Very Excited Over Federal Cannabis Legalization Efforts in U.S. House and Senate to Change Medical Cannabis Laws
PR Newswire - Wed Jul 30, 6:30AM CDT
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is extremely excited to report federal cannabis legalization efforts in U.S. House and Senate to change medical cannabis laws across the country. This can be a major game changer for Cannabis Science's efforts to commence its cannabis treatments nationwide for a number of targeted critical ailments.
AIDS Related Kaposi's Sarcoma Therapeutics Pipeline Review 2014 - 5 Companies & 5 Drug Profiles
M2 - 2 hrs 24 mins ago
Research and Markets (http://www.researchandmarkets.com/research/2fddlb/aids_related) has announced the addition of the "AIDS - Related Kaposi's Sarcoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for AIDS - Related Kaposi's Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for AIDS - Related Kaposi's Sarcoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - Aphios Corporation - CytRx Corporation - Cannabis Science, Inc. - Biogenomics Limited Drug Profiles - aldoxorubicin - selumetinib sulfate - paclitaxel nanosomal - CS-TATI-1 - interferon alfa-2a For more information visit http://www.researchandmarkets.com/research/2f...ds_related
Cannabidiol "CBD" Products Lead Industrial Hemp Sales As Scientific & Clinical Studies Underscore CBD's Potential - Company Exceeds Sales as Shipping Orders Begin
PR Newswire - Wed Sep 10, 7:45AM CDT
Marijuana & Cannabis industry experiences continued growth as emerging companies develop new cannabis opportunities as a result of recent clinical studies, reports provided on latest product developments from various sector related companies: Flameret Inc. (OTC: FLRE), Cannabis Science Inc. (OTC: CBIS), Medical Marijuana Inc. (OTC: MJNA), Terra Tech Corp. (OTC: TRTC), American Green Inc. (OTC: ERBB) and Easton Pharmaceuticals Inc. (OTC: EAPH)
NTRR: Feds Increase Cannabis Production as Demand Soars
Business Wire - Thu Sep 04, 4:00AM CDT
As Neutra Corp. (OTCBB:NTRR) prepares to debut revolutionary new indoor horticulture tools in a hungry marketplace, the demand for medical cannabis has grown so strong that even the federal government is increasing its production of the herb.
Cannabis Science Provides Updated Guidance on its Current Pre-Clinical Drug Development Programs Beginning with the Scientific Cannabis Cultivation Programs in Europe and North America, Testing Multiple Cannabis Strains for Multiple Critical Ailments
PR Newswire - Tue Aug 26, 12:17PM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to provide a guidance report on its current pre-clinical drug development programs underway, beginning with the scientific cannabis cultivation programs in Europe and North America, testing multiple cannabis strains for multiple critical ailments.
Cannabis Science, Inc. (CBIS) In Final Negotiations To Acquire British Columbia Company That Has Submitted 'Marihuana For Medical Purposes' License Application To Health Canada
PR Newswire - Mon Aug 25, 10:17AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that it is in the final stages of negotiations for the acquisition of a company that has applied for a "Marihuana for Medical Purposes" (Canada) license with Health Canada. The application includes a site located in British Columbia, Canada with a highly experienced and professional team. The target company currently produces cannabis under the "Marihuana Medical Access Regulations" (Canada).
Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France
PR Newswire - Fri Aug 22, 7:51AM CDT
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce its sponsorship of UFCM iCare's third international medical cannabis conference taking place at the Faculty of Medicine of Strasbourg, France, on October 22, 2014. The multilingual conference brings together industry experts with other stakeholders, such as researchers, health professionals, and patients, to discuss the development of medical cannabis in Europe and North America.
NTRR: U.S. Cannabis Market Poised to Grow with November Ballots
Business Wire - Thu Aug 21, 7:31AM CDT
The U.S. cannabis market appears primed to continue its unprecedented growth this year with 17 votes on the herb scheduled for the November general election. By that time, Neutra Corp. (OTCBB: NTRR) plans to be in production on its groundbreaking new Diamond Anvil vaporizer pen.
Cannabis Science, Inc. (CBIS) Increases Equity Position to 50.1% in Michigan Green Technologies LLC, Positioning Company as Leader in Evolving Michigan Medical Cannabis and Hemp Industries
PR Newswire - Mon Aug 11, 10:16AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, signs a binding letter of intent with its existing Michigan partners, increasing Cannabis Science's equity position from 20% to 50.1% in its joint venture in the Michigan medical cannabis and hemp markets, Michigan Green Technologies LLC (MGT).
Cannabis Science In Final Negotiations To Establish Its First Medical Cannabis Facilities In Canada
PR Newswire - Thu Aug 07, 10:55AM CDT
Cannabis Science, Inc. (OTC-QB:CBIS), a U.S. company specializing in cannabis formulation-based drug development and related consulting, is in the final stages of launching a new joint venture company for the purpose of acquiring, financing, building, owning and operating medical cannabis facilities, including dispensaries and growing operations, throughout Canada.
NTRR: Small Businesses Seize Big Opportunities in Cannabis Industry
Business Wire - Thu Aug 07, 9:16AM CDT
Rapidly evolving laws and enforcement have opened major opportunities in the U.S. cannabis sector for start-ups and small businesses. As new markets continue to emerge, Neutra Corp. (OTCBB: NTRR) is preparing to release new technology to capitalize on the nascent industry's "gold rush."
Cannabis Science, Inc. (CBIS) Encouraged by Florida Medical Cannabis Voter Support of 88 Percent; Florida Referendum in November Seen as Key Tipping Point
PR Newswire - Tue Aug 05, 10:23AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is encouraged by recent polling data by Quinnipiac University showing widespread support among voters in Florida for November's upcoming constitutional referendum on medical cannabis. The most recent study shows 88 percent of Florida voters are in favor of cannabis for medical uses.
Novus Acquisition & Development MMJ MedPlan Network Is A Contender
ACCESSWIRE - Tue Aug 05, 8:48AM CDT
Whitefish, MT / Aug 5, 2014 / As the Green Rush continues to gain political and cultural momentum across the country, shockwaves are being felt by all the primary players, from suppliers to patients, as the rapidly growing marijuana (MMJ) sector blows through each successive regulatory barrier. Even though 23 states (including DC) have enacted laws to legalize medical marijuana, the sector remains highly fragmented.
NTRR: Cannabis Boom Continues as New Markets Open
Business Wire - Tue Aug 05, 4:41AM CDT
As Neutra Corp. (OTCBB: NTRR) prepares to begin manufacturing and distributing its subsidiary's groundbreaking new vapor pen product, demand for cannabis-related products has taken another jump as recreational sales begin in the state of Washington.
Cannabis Science Initiates Pre-Clinical Studies on Cannabinoid Formulations in Neurological Diseases Including Sleep Disorders with the Highly Reputable Institute for Health and Science on Ageing - INRCA - in Italy
PR Newswire Europe - Mon Aug 04, 8:25AM CDT
Cannabis Science, Inc. (OTCQB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting is announcing that through its wholly-owned subsidiary, Cannabis Science International Holding BV, has signed an agreement with the prestigious Institute for Research, Hospitalization and Health Care on Ageing (INRCA) in Italy. The agreement provides for toxicity and efficacy studies of cannabinoid formulations performed in animal models for neurobehavioral diseases including sleep disorders.
Dr. Robert Melamede Joins Cannabis Professional University in Charlotte, NC at Business Seminar
PRWeb - Mon Aug 04, 5:37AM CDT
Cannabis Professional University announces that world-renowned medical cannabis research expert Dr. Robert Melamede, a Ph.D. in Molecular Biology and Biochemistry, has been added to the list of speakers at the Cannabis Business Seminar in Charlotte, North Carolina on Sunday August 3 from 9 am until 5 pm at the Sheraton Charlotte Airport Hotel.
Cannabis Science Initiates Scientific Cultivation Programs to Test Multiple Strains of Cannabis to Obtain Extract Formulations for Clinical Drug Development Targeting Multiple Critical Ailments Starting with Cancer and Neurological Disorders
PR Newswire - Thu Jul 31, 10:07AM CDT
Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce that it has commenced production of multiple strains of cannabis and European Union certified hemp varieties to initiate scientific research to select the best strains for development of proprietary formulations for clinical drug development to bring the cannabis formulations to market for critical ailments such as cancer and neurological disorders.
CBIS Very Excited Over Federal Cannabis Legalization Efforts in U.S. House and Senate to Change Medical Cannabis Laws
PR Newswire - Wed Jul 30, 6:30AM CDT
Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is extremely excited to report federal cannabis legalization efforts in U.S. House and Senate to change medical cannabis laws across the country. This can be a major game changer for Cannabis Science's efforts to commence its cannabis treatments nationwide for a number of targeted critical ailments.
